Association of Immunoscore, CD73 Expression and 53BP1 Expression with Neoadjuvant Chemoradiotherapy Efficacy in Patients with Locally Advanced Rectal Cancer
Received Date : 17 Nov 2022
Accepted Date : 15 Feb 2023
Available Online : 03 Mar 2023
Doi: 10.37047/jos.2022-94374 - Article's Language: EN
J Oncol Sci.
This is an open access article under the CC BY-NC-ND license
Objective: This study aimed to determine the relationship between immunoscore, CD73 expression, and P53 binding protein 1 (53BP1) expression in patients with locally advanced rectal cancer who received neoadjuvant chemoradiotherapy (nCRT) at the time of diagnosis and after treatment. Material and Methods: The patients with locally advanced rectal cancer treated with nCRT at diagnosis and after treatment were included and immunoscore, CD73 expression, and 53BP1 expression were evaluated. Results: A total of 53 patients were included in the study. Higher immunoscore and CD73 expression in the stroma (p=0.029 and p=0.011, respectively) were observed in the pathology specimen, in patients who responded well to nCRT before neoadjuvant treatment than that in patients who did not respond well. However, no association was noted between CD73 expression in tumor cells and pathological response (p=0.874). The immunoscore at diagnosis (p=0.087), 53BP1 expression (p=0.871), and CD73 expression in the stroma (p=0.053) did not correlate with 3-year disease-free survival (DFS). In contrast, an association between CD73 expression level in tumor cells (p=0.014), tumor regression grade (p=0.041), and pathological complete response (p=0.011) and 3-year DFS was found to be statistically significant. Conclusion: Our study revealed that in addition to tumor-related factors, host-related factors were associated with treatment response. A significant association was observed between immunoscore, CD73 expression, and neoadjuvant therapy response. Markers that can predict the response to nCRT are still needed, and more studies should be conducted to figure out how well immunomarkers work in this field.
  1. Glynne-Jones R, Wyrwicz L, TiretE, et al; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines fordiagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22-iv40. Erratum in: AnnOncol. 2018;29(Suppl 4):iv263. [Crossref]  [PubMed] 
  2. Nilsson PJ, van Etten B, HospersGA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locallyadvanced rectal cancer--the RAPIDO trial. BMC Cancer. Jun 2013;13:279. [Crossref]  [PubMed]  [PMC] 
  3. Conroy T, Lamfichekh N, EtiennePL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation inpatients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, aUNICANCER GI trial. American Society of Clinical Oncology. 2020;38(15_suppl):4007. [Crossref] 
  4. Klinakis A, Karagiannis D, RampiasT. Targeting DNA repair in cancer: current state and novel approaches. Cell Mol Life Sci.2020;77(4):677-703. [Crossref]  [PubMed] 
  5. Mirza-Aghazadeh-Attari M,Mohammadzadeh A, Yousefi B, Mihanfar A, Karimian A, Majidinia M. 53BP1: A key player of DNAdamage response with critical functions in cancer. DNA Repair (Amst). 2019 Jan;73:110-119. [Crossref]  [PubMed] 
  6. Huang A, Xiao Y, Peng C, et al.53BP1 expression and immunoscore are associated with the efficacy of neoadjuvantchemoradiotherapy for rectal cancer. Strahlenther Onkol. 2020;196(5):465-473. [Crossref]  [PubMed] 
  7. Stewart GS, Stankovic T, Byrd PJ,et al. RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damagesignaling. Proc Natl Acad Sci U S A. 2007;104(43):16910-16915. [Crossref]  [PubMed]  [PMC] 
  8. Yao J, Huang A, Zheng X, et al.53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil byinhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol. 2017;143(3):419-431. [Crossref]  [PubMed] 
  9. Pagès F, Mlecnik B, Marliot F, et al. International validation of theconsensus Immunoscore for the classification of colon cancer: a prognostic and accuracystudy. Lancet. 2018;391(10135):2128-2139. [PubMed] 
  10. Matsutani S, Shibutani M, MaedaK, et al. Significance of tumor-infiltrating lymphocytes before and after neoadjuvanttherapy for rectal cancer. Cancer Sci. 2018;109(4):966-979. [Crossref]  [PubMed]  [PMC] 
  11. Vijayan D, Young A, Teng MWL,Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer.2017;17(12):709-724. Erratum in: Nat Rev Cancer. 2017;17(12):765. [Crossref]  [PubMed] 
  12. Serra S, Horenstein AL, VaisittiT, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia createslocal conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-6152. [Crossref]  [PubMed]  [PMC] 
  13. Zhang B, Song B, Wang X, et al.The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma.Tumour Biol. 2015;36(7):5459-5466. [Crossref]  [PubMed] 
  14. Anitei MG, Zeitoun G, Mlecnik B,et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer.Clin Cancer Res. 2014;20(7):1891-1899. [Crossref]  [PubMed] 
  15. Bi J, Huang A, Liu T, Zhang T, Ma H. Expression of DNA damage checkpoint53BP1 is correlated with prognosis, cell proliferation and apoptosis in colorectal cancer.Int J Clin Exp Pathol. 2015;8(6):6070-6082. [PubMed]  [PMC] 
  16. Tsukui H, Horie H, Koinuma K, etal. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectalcancer model. BMC Cancer. 2020;20(1):411. [Crossref]  [PubMed]  [PMC] 
  17. Banias L, Jung I, Bara T, et al. Immunohistochemical-based molecularsubtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymaltransition. Oncol Lett. 2020;19(2):1487-1495. [PubMed]  [PMC] 
  18. Vecchio FM, Valentini V, MinskyBD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes afterpreoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):752-760. [Crossref]  [PubMed] 
  19. Ngan SY, Burmeister B, Fisher RJ,et al. Randomized trial of short-course radiotherapy versus long-course chemoradiationcomparing rates of local recurrence in patients with T3 rectal cancer: Trans-TasmanRadiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827-3833. Erratum in: JClin Oncol. 2013;31(3):399. [Crossref]  [PubMed] 
  20. Bujko K, Nowacki MP,Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomizedtrial comparing preoperative short-course radiotherapy with preoperative conventionallyfractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215-1223. [Crossref]  [PubMed] 
  21. Pettersson D, Lörinc E, Holm T,et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens forrectal cancer. Br J Surg. 2015;102(8):972-978; discussion 978. [Crossref]  [PubMed]  [PMC] 
  22. Siddiqui MRS, Simillis C, HunterC, et al. A meta-analysis comparing the risk of metastases in patients with rectal cancerand MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. Br JCancer. 2017;116(12):1513-1519. [Crossref]  [PubMed]  [PMC] 
  23. Wu XR, He XS, Chen YF, et al.High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J SurgOncol. 2012;106(2):130-137. [Crossref]  [PubMed] 
  24. Stagg J, Divisekera U, Duret H,et al. CD73-deficient mice have increased antitumor immunity and are resistant toexperimental metastasis. Cancer Res. 2011;71(8):2892-2900. [Crossref]  [PubMed] 
  25. Angell HK, Bruni D, Barrett JC,Herbst R, Galon J. The immunoscore: colon cancer and beyond. Clin Cancer Res.2020;26(2):332-339. [Crossref]  [PubMed] 
  26. Galon J, Mlecnik B, Marliot F, et al. Validation of the Immunoscore (IM)as a prognostic marker in stage I/II/III colon cancer: Results of a worldwideconsortium-based analysis of 1,336 patients. American Society of Clinical Oncology.2016;34(15_suppl):3500. [Link] 
  27. Pagès F, André T, Taieb J, et al.Prognostic and predictive value of the Immunoscore in stage III colon cancer patientstreated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. AnnOncol. 2020;31(7):921-929. Erratum in: Ann Oncol. 2020;31(9):1276. [Crossref]  [PubMed] 
  28. El Sissy C, Kirilovsky A, Van denEynde M, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvanttreatment and selects patients with rectal cancer eligible for a watch-and-wait strategy.Clin Cancer Res. 2020;26(19):5198-5207. [Crossref]  [PubMed] 
  29. Zhang C, Wang X, Han J, et al.Histological tumor response to neoadjuvant chemotherapy correlates to Immunoscore incolorectal cancer liver metastases patients. J Surg Oncol. 2021;124(8):1431-1441. [Crossref]  [PubMed]